|Bid||107.50 x 1000|
|Ask||108.68 x 900|
|Day's Range||106.56 - 120.57|
|52 Week Range||56.76 - 131.87|
|Beta (3Y Monthly)||1.47|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx
Which stocks can go from zero to one hundred overnight? Wall Street pros point to biotechs. For more risk-tolerant investors, these names represent exciting opportunities as a single positive catalyst such as promising trial results or a favorable FDA ruling can send shares skyrocketing. Naturally, a negative outcome can have the opposite effect.As a result, it can be hard for even the most seasoned investors to gauge which biotech stocks are primed for explosive growth. Not to worry, there are strategies that can help make this process a little easier like taking a cue from the analysts.With this in mind, we turned to Wedbush’s Liana Moussatos to get some investing inspiration. Using TipRanks.com, we got a closer look at three of her Buy-rated picks in the space that could more than double in 2020.Aquestive Therapeutics (AQST)Aquestive has developed a novel approach to delivering the active ingredients in established drugs using its unique PharmFilm technology. On the heels of a favorable FDA decision, Moussatos tells investors that this latest development solidified her position that now is the time to buy.On Monday, AQST broke the news that the FDA had approved its Exservan drug for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. The disease is characterized by the deterioration of the neurons that control voluntary muscles. As patients with ALS often have trouble swallowing, Exservan eliminates the need to do so because it adheres to the tongue and dissolves quickly.Moussatos points out that this drug is able to meet the huge unmet need for ALS patients as it doesn’t require swallowing a tablet with water, suggesting that it could be a major profit generator. She stated, “We estimate Exservan gross sales worldwide of a little over $20 million starting in 2025.”This comes after AQST’s solid Q3 performance featuring a revenue beat. On top of this, management bumped up its revenue guidance for 2019 to between $45 million and $47 million, up from the original forecast of $38 million to $45 million. With the sales of its already approved Sympazan drug to treat Lennox-Gastaut Syndrome (LGS) continuing to grow, Moussatos predicts that annual U.S. Sympazan sales could reach $108 million in 2027.Based on all that, the analyst reiterated an Outperform rating on AQST while lifting the price target by $1 to $37. This implies that shares could soar a whopping 391% over the next twelve months.In terms of other analyst activity, it has been relatively quiet. 2 Buy ratings assigned in the last three months add up to a ‘Moderate Buy’ analyst consensus. In addition, the $25 average price target puts the upside potential at 225%. (See Aquestive stock analysis on TipRanks)Intercept Pharmaceuticals (ICPT)Intercept is a rising star in the biotech industry, developing small-molecule treatments for progressive non-viral liver diseases.Investors got some good news on Monday as the FDA just accepted ICPT’s obeticholic acid (OCA) NDA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH) and granted priority review. With the PDUFA date scheduled for March 26, 2020 and a possible AdCom, Moussatos believes that big things are on the way.“Based on robust safety and efficacy data to date, we anticipate a positive AdCom vote and approval for OCA/NASH and project potential achievement of blockbuster ($1 billion) revenue in 2024 after a potential U.S. launch in October 2020,” she commented.At the American Association for the Study of Liver Diseases, the company presented data from its Phase 3 REGENERATE trial. The findings suggest that OCA-treated patients demonstrated continued improvement across several low-cost and noninvasive markers of fibrosis and NASH. While some patients reported that after treatment they experienced significant pruritus, or itchiness of the skin, it didn’t affect measures of quality of life.As a result, Moussatos notes that she is staying with the bulls. Along with her Outperform rating, the analyst increased the price target from $243 to $257. This updated target conveys her confidence in ICPT’s ability to climb 167% higher in the next twelve months.In general, the rest of the Street is in agreement. With 9 Buys and 1 Hold received in the last three months, the consensus is that ICPT is a ‘Strong Buy’. While less than Moussatos’ forecast, the $151 average stock-price forecast still indicates substantial upside potential of 57%. (See Intercept stock analysis on TipRanks)Clearside Biomedical (CLSD)Clearside is best known for offering a uniquely designed suprachoroidal space (SCS) microinjection platform to improve the delivery of drugs to treat various eye diseases. Its lead candidate, Xipere, was developed to treat macular edema associated with noninfectious uveitis (ME-NIU), which can threaten eyesight.Following the company’s announcement that it had postponed its Xipere for ME-NIU NDA resubmission as a result of delays at its contract manufacturer, investors have definitely expressed concern. Back in October, CLSD received a complete response letter (CRL) for Xipere from the FDA requesting further information and analysis but not any additional clinical efficacy studies before approval. That being said, Moussatos remains optimistic as she expects potential approval and commercial launch of Xipere in the U.S. in Q4 2020 and Q1 2021, respectively.She also notes that CLSD is planning to file an IND application sometime in mid-2020 for a proprietary suspension of axitinib (CLS-AX) for suprachoroidal injection. Axitinib is a small molecule multi-receptor tyrosine kinase inhibitor that the company hopes will be an effective treatment for advanced renal cell carcinoma.Despite posting an EPS loss of $0.17 per share in its third quarter, the Wedbush analyst advocates patience as she sees huge gains in store based on these two programs. To this end, she reaffirmed her bullish thesis. Her $3 price target brings the potential twelve-month rise to 138%.Looking at the consensus breakdown, analysts are split right down the middle when it comes to CLSD. 1 Buy vs 1 Hold lend itself to a ‘Moderate Buy’ Street consensus. Additionally, the $3 average price target places the upside potential right in-line with Moussatos’ estimate. (See Clearside stock analysis on TipRanks)
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
Intercept Pharmaceuticals stock rocketed Monday after FDA regulators granted its NASH treatment priority review and after competing biotech company CymaBay scrapped its rival drug.
Intercept (ICPT) delivered earnings and revenue surprises of -10.21% and -2.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you're interested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), then you might want to consider its beta (a...
A biotech company that started in Israel 21 months ago and moved to San Francisco this year wants to raise $70 million through an initial public offering to tackle one of the hottest areas of drug development. Fourteen-employee 89bio Inc. stated in a Securities and Exchange Commission filing Friday that it plans to use the cash to complete mid-stage clinical trials of its signature drug against the fatty liver disease known as nonalcoholic steatohepatitis, or NASH, and severe hypertriglyceridemia as well as for drug manufacturing. NASH has attracted deep-pocketed drug companies such as Foster City-based Gilead Sciences Inc. (NASDAQ: GILD), South San Francisco's NGM Biopharmaceuticals Inc. (NASDAQ: NGM), Pfizer Inc. (NYSE: PFE) and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) and an army of smaller companies, such as South San Francisco's Akero Therapeutics Inc. (NASDAQ: AKRO).
Enanta Pharmaceuticals stock careened toward its lowest point in two years Thursday after its nonalcoholic steatohepatitis treatment didn't outperform a rival from Intercept Pharmaceuticals.
Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
The NASH liver disease treatment market is growing with biotech companies like Intercept and Genfit in late-stage tests. Experts say the market for a successful drug could be worth billions.